Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资
Cytokinetics宣布定价6.5亿美元扩大规模可转换优先票据发行;为2027年可转换票据部分进行再融资
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.